RenovoRx, Inc.

RenovoRx, Inc. (RNXT) priced its initial public offering on Aug 27, 2021 at $9.00 per share, raising $16.6M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $75.5M. Roth Capital was lead-left underwriter, joined by Maxim Group. Sheppard Mullin advised the company and Ellenoff Grossman & Schole advised the underwriters.

RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing local treatments for solid tumors. Its lead candidate, RenovoGem, is in a Phase 3 registrational trial and uses the RenovoTAMP platform with the FDA-cleared RenovoCath delivery system.

Status

IPO

Ticker

RNXT

Exchange

Nasdaq Capital Market

Priced

Aug 27, 2021

IPO price

$9.00

Raised

$16.6M

Market cap at IPO price

$75.5M

First filed

Jul 21, 2021

Underwriters

Roth Capital and Maxim Group

Company counsel

Sheppard Mullin

Underwriters' counsel

Ellenoff Grossman & Schole

Sector

Healthcare

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.